Heidelberg, Germany, and Cambridge, MA, USA, December 16, 2021 – Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today provided a development update on the phase 3 trial of SHR8058 eye drops (perfluorohexyloctane) for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD) conducted by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”) (SSE: 600276) in the People’s Republic of China showing statistically significant topline results compared to 0.6% sodium chloride solution.1
Hengrui Pharma has completed the Phase 3 clinical trial (SHR8058-301) which enrolled 312 patients at 17 clinical sites in the People’s Republic of China. SHR8058-301 was a multi-center, randomized, double-masked, saline-controlled clinical trial and was designed to evaluate the efficacy and safety of SHR8058 eye drops (100% perfluorohexyloctane) for the treatment of signs and symptoms of DED associated with Meibomian gland dysfunction. SHR8058-301 evaluated its primary efficacy at eight weeks.2
The trial met its prespecified primary sign endpoint improvement of total corneal fluorescein staining (tCFS) and its prespecified primary symptom endpoint improvement of eye dryness score of the Visual Analogue Scale (VAS) at eight weeks with high statistical significance. The trial showed an excellent safety and tolerability profile for SHR8058 eye drops (perfluorohexyloctane) comparable to placebo.
Hengrui Pharma expects to submit a pre-NDA communication application to the National Medical Products Administration (NMPA)’s Center for Drug Evaluation (CDE) in the People’s Republic of China in the near term future.
About SHR8058 eye drops (perfluorohexyloctane)
SHR8058 eye drops is an investigational, proprietary, water-free and preservative-free solution, based on Novaliq’s EyeSol® technology. In 2019, Hengrui Pharma and Novaliq announced a strategic collaboration under which Hengrui Pharma secured exclusive rights to develop, manufacture, and commercialize NOV03 (local drug name SHR8058 eye drops) and CyclASol® (local drug name SHR8028 Eye Drops) in China.
About Novaliq
Novaliq is a biopharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology. Novaliq offers an industry-leading portfolio addressing today’s unmet medical needs of millions of patients with eye diseases. Novaliq GmbH is headquartered in Heidelberg, Germany and Novaliq Inc. has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech holding GmbH & Co. KG, an active investor in Life and Health Sciences companies. More on www.novaliq.com.
References
Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology NOV03 Consistently Met Primary Endpoints for Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction NOV03 PDUFA Action Date is June 28, 2023
VAUGHAN, Ontario, and HEIDELBERG, Germany, March 22, 2023 – Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced that American Journal of Ophthalmology has published results from MOJAVE, the second pivotal Phase 3 trial for NOV03 (perfluorohexyloctane). NOV03 is being investigated to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). Results from the first pivotal Phase 3 trial, GOBI, were published earlier this year in Ophthalmology. The U.S. Food and Drug Administration (FDA) assigned NOV03 a Prescription Drug User Fee Act (PDUFA) action date of June 28, 2023.Heidelberg, Germany, and Cambridge, MA, USA, Feb 8, 2023 – Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced its plans for filing a Marketing Authorisation Application (MAA) for CyclASol® (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED) in the European Union.